Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
47 hedge funds and large institutions have $11.8M invested in Acorda Therapeutics in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 22 closing their positions.
122% more call options, than puts
Call options by funds: $226K | Put options by funds: $102K
19% more capital invested
Capital invested by funds: $9.86M → $11.8M (+$1.92M)
22% less funds holding
Funds holding: 60 → 47 (-13)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
Top Buyers
Top Sellers
ACOR Hedge Fund Activity: Q4 2020 in Review
47 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2020, worth a combined $11.8M — up 19% from $9.86M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ACOR and 9 opened new positions — a net loss of 13 holders — while 15 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $190K. The largest seller was Point72 Asset Management, cutting an estimated $840K.
- 47 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2020, down from 60 in Q3 2020.
- Funds reported $11.8M of Acorda Therapeutics stock for Q4 2020, up 19% quarter-over-quarter.
- 9 funds opened new Acorda Therapeutics positions in Q4 2020 and 22 closed out, a net change of -13 holders.
- The largest Acorda Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $190K added.
- The largest Acorda Therapeutics seller in Q4 2020 was Point72 Asset Management, an estimated $840K sold.
Based on aggregated 13F filings for Q4 2020.